Exchange: NASDAQ·Updated 07:30 PM EST

RNAC News

News
all
press releases
Bears are Losing Control Over Cartesian Therapeutics, Inc. (RNAC), Here's Why It's a 'Buy' Now
Cartesian Therapeutics, Inc. (RNAC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
Bears are Losing Control Over Cartesian Therapeutics, Inc. (RNAC), Here's Why It's a 'Buy' Now
Cartesian Therapeutics, Inc. (RNAC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
More News
The consensus price target hints at a 379.6% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
uniQure (QURE) delivered earnings and revenue surprises of -4.76% and -27.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Amgen (AMGN) delivered earnings and revenue surprises of +12.37% and +4.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
(RTTNews) - Tuesday, Cartesian Therapeutics (RNAC) reported additional retreatment data for investigational CAR-T therapy Descartes-08 showing sustained improvements in patients with generalized myasthenia gravis (MG...
Nasdaq News: Markets
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
Zacks
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
As the market enters the final stretch of trading, one story is dominating virtually every trading desk on Wall Street: the historic debut of SpaceX. The company's long-awaited public offering has generated extraordinary volume, massive investor interest, and renewed enthusiasm across multiple high-growth sectors including space infrastructure, artificial intelligence, biotechnology, and advanced communications. $NTHI, $SPCX, $ELVN, $POET, $RNAC, $ALOY
24-7 Market News
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.read more...
Benzinga
Wedbush restated an "outperform" rating and set a $38.00 price objective on shares of Cartesian Therapeutics in a research report on Friday...
MarketBeat

Advertisement|Remove ads.